Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
The month ahead: November’s upcoming events
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
